Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) disclosed Tuesday that its antibody cocktail showed positive results in early-stage trials for hospitalized patients. What Happened: Regeneron's treatment, a blend of two antibodies — Casirivimab and Imdevimab, was tested in patients hospitalized for COVID-19 infection requiring low-flow oxygen.

Regeneron COVID-19 Antibody Cocktail Shows Positive Response In Hospitalized Patients

Costco

Salesforce

D.R. Horton

FedEx

Salesforce is still a long-term buy despite its nearly 10% month-to-date decline, two traders say.

How two traders would play the 2020 outperformers that reversed course in December

TARRYTOWN, N.Y., Dec. 29, 2020 /PRNewswire/ -- Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation As in earlier outpatient trial, immune status when patients entered the trial was a...

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen

Griffon

MasTec

QUALCOMM

Qorvo

Rocket Companies, Inc.

Skyworks Solutions

Investors already enjoying strong gains in the year may want to look at these short-term stocks to buy heading into the new year. The post 7 Short-Term Stocks To Buy for a Happy New Year   appeared first on InvestorPlace.

7 Short-Term Stocks To Buy for a Happy New Year  

The shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are up 1.8% at $505.38 at last check.

Regeneron Stock Boosted on Published Results

Gilead Sciences

Paying an excellent price for high-flying biotech stocks and holding has been a profitable investing strategy.

2 Best Biotech Stocks to Buy in December

TARRYTOWN, N.Y., Dec. 17, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab...

New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19

BioMarin Pharmaceutical

Bristol-Myers

Eli Lilly

McKesson

With 2020 almost over and the new year just two short weeks away, many investors are resetting for what could be a volatile 2021.

Goldman Sachs Adds Pharmaceutical Giant to Conviction List of Top Stocks to Buy

TARRYTOWN, N.Y., Dec. 16, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021. The presentation is scheduled for 8:20 a.m. Eastern Time and may be accessed from...

Regeneron Announces Presentation at the 39th Annual J.P. Morgan Healthcare Conference

This biotech company is investigating an already successful product -- now to be tested as a nasal spray.

Is This Stock On Its Way to Making a COVID-19 Vaccine Obsolete?

Some of the most oversold stocks on the market could be worth a second look. Quint Tatro of Joule Financial and Craig Johnson of Piper Sandler discuss.

One of the most oversold stocks could be ready for a comeback

bluebird bio

Johnson & Johnson

Legend Biotech

Targeting BCMA is all the rage, but who will come out on top?

ASH Annual Meeting: Drugmakers Battle for Multiple Myeloma

Drugmakers are targeting B-cell maturation antigen in different ways.

Here's the Hot Target for Multiple Myeloma Drugs

Moderna

These companies haven't even started to report revenue from their COVID-19 projects yet.

2 Best Coronavirus Stocks to Buy Right Now

Alexion Pharma

Amgen

Biogen

Vertex Pharmaceuticals

The short interest data is out for November 30, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Which Big Biotechs Short Sellers Favor Now

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents on Investor Event ASH 2020 Conference Call Transcript

Regeneron (REGN) releases encouraging data from early-stage study on REGN5458 at the ASH 2020.

Regeneron (REGN) Posts Upbeat Data on Myeloma Candidate at ASH

TARRYTOWN, N.Y., Dec. 5, 2020 /PRNewswire/ -- 63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients with ≥6 months of follow-up, 83% have ongoing...

Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

Regeneron (REGN) Down 16.4% Since Last Earnings Report: Can It Rebound?

While Regeneron stock is up 38% since the start of the year, it has dropped around 20% from its July highs of around $660. After the recent decline, REGN stock could offer an upside in the near term, as the company's revenues in the last three quarters have grown by 29%, primarily aided by market.

Regeneron Stock Looks Attractive After A 20% Correction

NEW YORK--(BUSINESS WIRE)-- #REGN--Scott+Scott Continues Investigation of Regeneron Pharmaceuticals, Inc.'s Directors and Officers for Breach of Fiduciary Duty – REGN

Scott+Scott Attorneys at Law LLP Continues Investigation of Regeneron Pharmaceuticals, Inc.'s Directors and Officers for Breach of Fiduciary Duty – REGN

Regeneron Pharmaceuticals' (REGN) Management Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference (Transcript)

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Evercore ISI 3rd Annual HealthCONx Conference (Transcript)

AbbVie

Inovio Pharmaceuticals

Novavax

Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.

4 Pharmaceutical Stocks That Aren't Worth Their Outsized 2020 Gains

Sanofi

Regeneron (REGN) and Sanofi win EC nod for Dupixent for the indication of severe atopic dermatitis in children 6 to 11 years of age.

News for Regeneron Pharmaceuticals Stock (REGN)